Research programme: angiogenesis inhibitors - Innovation Pharmaceuticals

Drug Profile

Research programme: angiogenesis inhibitors - Innovation Pharmaceuticals

Alternative Names: PMX-20005

Latest Information Update: 09 Jun 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PolyMedix
  • Class Small molecules
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Age-related macular degeneration; Cancer; Inflammation

Most Recent Events

  • 07 Jun 2017 Cellceutix is now called Innovation Pharmaceuticals
  • 09 Sep 2013 Suspended - Preclinical for Age-related macular degeneration, Cancer and Inflammation in USA (unspecified route)
  • 04 Sep 2013 Cellceutix has acquired the assets of PolyMedix
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top